Quel est le prix pour Mabwell (Shanghai) Bioscience Co., Ltd. (688062)

Le prix pour Mabwell (Shanghai) Bioscience Co., Ltd. (688062) est $4.29

Quelle est la capitalisation boursière pour Mabwell (Shanghai) Bioscience Co., Ltd. (688062)

La capitalisation boursière pour Mabwell (Shanghai) Bioscience Co., Ltd. (688062) est $1.71B

Bénéfices de Mabwell (Shanghai) Bioscience Co., Ltd. (688062)

Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.

Année	Bénéfices	Changez
Pas assez de données pour les dates fournies.

Année

Bénéfices

Changez

Pas assez de données pour les dates fournies.

Entreprise	Bénéfices	Différence de bénéfices	Pays
Vertex Pharmaceuticals Incorporated VRTX.US	$5.27B	-	US
Argenx SE ARGX.US	$1.95B	-	NL
CSL Limited CSL.AX	$-4.02B	-	AU
Moderna, Inc. MRNA.US	$-3.09B	-	US
Lonza Group AG LONN.SW	-	-	CH

Entreprise

Bénéfices

Différence de bénéfices

Pays